Portable Health Files Improve Quality of Care and Health Outcomes: a Randomized Controlled Trial (PHF-RCT)

July 31, 2017 updated by: Marissa Lassere, St George Hospital, Australia

A Randomized Controlled Trial of Portable Electronic(USB)and Paper Medical Records as an Adjunct to Usual Care (Portable Health File RCT): an Evaluation of Short Term Quality Measures and Long-term Clinical Outcomes

The PHF trial will assess the acceptability and long term outcomes resulting from the usage of electronic (carried by the patient on a USB memory device) and paper portable health files in a population with high intensity use of medical services. The rationale is that use of the portable health files provides a conduit of direct communication among health care providers of a patient's important health care information and this leads to better care and patient outcomes.

Primary hypothesis: Addition of a patient-held portable health file (PHF) to usual care improves patient outcome and quality-of-life compared to usual care alone.

Secondary hypothesis: Addition of patient-held portable health file (PHF) to usual care is acceptable and satisfactory to patients and their health care providers.

Study Overview

Detailed Description

A common problem faced by patients and clinicians in our health system is continuity of care and 'clinical handovers'. Few medical record technologies, paper or electronic, top down or bottom up, have been evaluated in a randomised clinical outcome trial to determine the clinical benefits and costs of 'shared' medical and health information. Furthermore, although there are many studies that have evaluated processes of care only a minority do so within a randomized design. Given that any difference is, possibly, small to moderate in magnitude, and given confounders, the use of a randomisation is an essential design requirement.

The first 12 months of the trial constitutes Stage 1 whose primary objective is to describe the acceptability and satisfaction of the our Portable Health Files, and other key process measures. The subsequent 36 months constitutes Stage 2 whose primary objective it to compare important clinical outcomes. The assigned treatment (i.e., the e-PHF or p-PHF) will be used for 4 years total.

To take into account a probable lag effect of the interventions, patients will also be followed for an additional 3 years beyond the conclusion of the randomised trial to see if there are any longer-term effects.

The trial is un-blinded so there will be a potential for bias in trial conduct and a potential for ascertainment bias in the determination of important clinical outcomes and quality-of-life. To reduce clinical outcome ascertainment bias a blinded Adjudication Committee will make the determination which out-of-hospital events are "serious". The other primary outcomes: mortality and all overnight hospitalizations are objective outcomes and are not subject to ascertainment bias.

Secondary outcomes include quality of life, quality measures uptake, investigations, medication use, medication errors, and adverse drug reactions. Utilities and costs will also be collected for cost-effectiveness analysis. Patient and provider acceptability and satisfaction with the PHFs will be also collected.

All primary analyses will be undertaken masked to randomized arm allocation.

Most secondary analyses including quality of life, quality measures uptake, investigations, medication use, medication errors, and adverse drug reactions, health utilities, health care utilisation and health care costs will also be undertaken masked to randomized arm allocation.

This Adjudication Committee will also monitor trial safety and scientific integrity.

Study Type

Interventional

Enrollment (Anticipated)

382

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New South Wales
      • Kogarah, New South Wales, Australia, 2217
        • St George Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Subjects must be of age 60 or greater
  2. Patients living independently in the community. Hostel care is acceptable, but patients that are not independent requiring full nursing home care are excluded.
  3. Subjects must have had six medical practitioner visits in the previous 12 months
  4. Subjects must have at least two of the following confirmed chronic diseases that require prescription oral or parenteral drug treatment or surgery and requiring at least annual specialist consultation: cardiovascular, respiratory, endocrine, renal, neurologic, gastrointestinal, hepatic, genitourinary, haematologic. infective, rheumatic, inflammatory, immunologic or neoplastic disease.

6. Subject's GP must have access to a computer during the consultation visit. 7. Subjects must have at least two medical specialists at least one of whom has access to a computer during the consultation visit.

8. Subjects must be able to understand the purpose of the trial and undergo full and valid informed consent.

Exclusion Criteria:

  1. Life expectancy of less than 12 months.
  2. Inability to carry a paper PHF or e-PHF and having no care-giver willing and able to accomplish same.
  3. Mentally unable to undertake valid informed consent.
  4. Patients who are not independent in the community, that cannot mobilise to see a specialist or requiring full nursing home care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Electronic (USB) Portable Health File
Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
Other Names:
  • Electronic Personal Health Record
  • Electronic Patient-Health Provider Shared Medical Record
  • Electronic Patient-Health Provider Shared Journal
  • Electronic Patient-carried Shared Medical Record
  • Electronic Patient-carried Continuity of Care Record
Experimental: Paper Portable Health File
Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
Other Names:
  • Paper Personal Health Record
  • Paper Patient-Health Provider Shared Medical Record
  • Paper Patient-Health Provider Shared Journal
  • Paper Patient-carried Shared Medical Record
  • Paper Patient-carried Continuity of Care Record
No Intervention: Usual standard of care
Patients randomized to this arm of the trial will not be given a Portable Health File. This arm is the concurrent control comparator arm.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Combined endpoint of deaths, hospitalisations (excepting day only hospitalisations), and serious out-of-hospital events
Time Frame: 48 months + 36 month extension

The primary outcome is the total number of important clinical events (all hospitalisations except same-day hospitalisations, all serious out-of-hospital events and deaths).

See above: The assigned treatment (i.e., the e-PHF or p-PHF) will be used for 4 years total. Patients will also be followed for an additional 3 years beyond the conclusion of the randomised trial to see if there are any longer-term lag effects.

48 months + 36 month extension

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life
Time Frame: every 12 months for 48 months
SF-36 and EQ-5D
every 12 months for 48 months
health service utilisation and health care costs
Time Frame: every 12 months for 48 months
Emergency Department encounters, General Practitioner and Specialist Encounters via record linkage, and their estimated costs by MBS and other costs data
every 12 months for 48 months
medication errors, duplicative investigations
Time Frame: every 12 months for 48 months
Questionnaire, Self-report PROs and CROs
every 12 months for 48 months
clinical workflow
Time Frame: every 6 months for 2 years then every 12 months until 48 months
Questionnaire, Self-report PROs and CROs
every 6 months for 2 years then every 12 months until 48 months
subject and health care provider acceptability and satisfaction with portable health files (PHF)
Time Frame: every 3 months for 12 months then every 6 months 24 months then every 12 months until 48 months
Questionnaire, Self-report PROs and CROs
every 3 months for 12 months then every 6 months 24 months then every 12 months until 48 months
guidelines uptake and documentation
Time Frame: every 6 months for 24 months then every 12 months until 48 months
Questionnaire, Self-report PROs and CROs
every 6 months for 24 months then every 12 months until 48 months
health literacy
Time Frame: every 12 months until 48 months
Questionnaire, Self-report PROs
every 12 months until 48 months
information technology and computer expertise
Time Frame: every 6 months for 24 months then every 12 months until 48 months
Questionnaire, Self-report PROs
every 6 months for 24 months then every 12 months until 48 months
adverse events
Time Frame: every 3 months for 24 months then every 6 months until 48 months
Questionnaire, Self-report PROs
every 3 months for 24 months then every 6 months until 48 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Marissa ND Lassere, MBBS PhD, St George Hospital and Univeristy of NSW
  • Principal Investigator: Kent R Johnson, MD, Newcastle University
  • Principal Investigator: George Rubin, MD, South East Sydney Area Health Service
  • Principal Investigator: Anthony Sara, MBBS MBA, South East Sydney Area Health Service
  • Principal Investigator: Andrew Parle, BSc (Hons) PhD, Consultant

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2010

Primary Completion (Anticipated)

March 1, 2019

Study Completion (Anticipated)

March 1, 2020

Study Registration Dates

First Submitted

March 8, 2010

First Submitted That Met QC Criteria

March 8, 2010

First Posted (Estimate)

March 9, 2010

Study Record Updates

Last Update Posted (Actual)

August 1, 2017

Last Update Submitted That Met QC Criteria

July 31, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • PHF-06-124-ML
  • NHMRC 455467 (Other Grant/Funding Number: NHMRC)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Personal Health Records

Clinical Trials on Electronic (USB) Portable Health File

3
Subscribe